Section Editors

Bertrand Tombal - Professor and Chairman, Service d’Urologie, Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium.

Bertrand Tombal

Professor and Chairman, Service d’Urologie, Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium.

Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine.

He is the Member of the Board of European Organization for Research and Treatment in Cancer (EORTC), the leading European academic research organization in the field of cancer, where he acts as chairman of the Clinical Trial Division and of the Genitourinary Cancer Group.

He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA.

Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003.

Professor Tombal is also member of Belgium College of Oncology, the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology.

Axel S Merseburger - Professor and Chairman of the Department of Urology in Lübeck, Germany

Axel S Merseburger

Professor and Chairman of the Department of Urology in Lübeck, Germany

Axel S Merseburger is the chairman of the Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Germany. Prof. Merseburger obtained his medical degree from Hannover Medical School in 2002 after a one-year academic research programme in Washington DC, USA, where he completed his MD thesis. In 2008, he accepted a staff position in Hannover and was promoted to associate Prof. in 2009; he obtained full Prof.ship in 2012.

Prof. Merseburger is board certified in urology and is a member of numerous national and international urological and oncological associations. In addition to serving as a reviewer and member of the editorial board of many journals, Prof. Merseburger is the associate editor of the ‘World Journal of Urology’ and Editor in Chief of the ‘Advanced Prostate Cancer Resource Centre’. Furthermore, he is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer. He serves as national and international principal investigator in several phase II/III clinical trials. Prof. Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has authored more the 200 peer review publications.

Special Feature

ESMO 2016 Immunotherapy for GU cancers: latest advances and future approaches The rapidly evolving field of immunotherapy in the treatment of genitourinary (GU) cancers was covered in a satellite symposium, sponsored by F. Hoffmann-La Roche, and held at the European Society for Medical Oncology (...

Latest Articles

Latest Videos

Video List based on Category on Node Page

Latest Videos

ESMO 2016 Immunotherapy for GU cancers: latest advances and future approaches The rapidly evolving field of immunotherapy in the treatment of genitourinary (GU) cancers was covered in a satellite symposium, sponsored by F. Hoffmann-La Roche, and held at the European Society for Medical Oncology (ESMO) congress, in Copenhagen on 9 October 2016. Chaired by Dr Elizabeth Pilmack, Philadelphia, PA,...
Dr. Howard Kaufman discusses the key findings of the PROCLAIM Registry and IL-2. FILMED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, JUNE 2016 COULD YOU GIVE US AN OVERVIEW OF THE RATIONALE BEHIND THE PROCLAIM REGISTRY? 00:10 – The Proclaim Registry was really designed to collect information on patients being treated with interleukin-2. The registry started with a...
Karim Fizazi - Filmed at the ECC 2015, Vienna Part 2/2: Karim Fizazi discusses the impact of recent research into prognostic and predictive tests in prostate cancer on the clinical outcomes.

Genitourinary Cancers INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Insight
The Role of Interleukin in the Treatment of Malignant Melanoma and Renal Cell Carcinoma Katrina Mountfort, Freelance Medical Writer for Touch Medical Media, UK